TL;DR: Tesamorelin is an FDA-approved synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to produce and release growth hormone naturally. Sold under the brand name Egrifta, it is the only FDA-approved treatment specifically for reducing visceral adipose tissue, with clinical trials showing approximately 15-18% reduction in deep abdominal fat over 26 weeks. Unlike exogenous HGH, tesamorelin preserves the body's natural pulsatile GH release pattern, maintaining feedback loops and offering a more favorable safety profile.
What Is Tesamorelin?
Tesamorelin (brand name: Egrifta/Egrifta SV) is a synthetic peptide analog of human growth hormone-releasing hormone (GHRH). It consists of the full 44-amino-acid sequence of endogenous GHRH with an added trans-3-hexenoic acid group at the N-terminus, which increases its stability and resistance to enzymatic degradation.
Developed by Theratechnologies Inc., tesamorelin received FDA approval in November 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy -- a condition characterized by abnormal fat distribution caused by antiretroviral therapy. It remains the only FDA-approved medication specifically indicated for the reduction of visceral adipose tissue (VAT).
Tesamorelin works by binding to GHRH receptors on the anterior pituitary gland, stimulating the synthesis and secretion of endogenous growth hormone. This is fundamentally different from injecting exogenous HGH, because tesamorelin preserves the body's natural regulatory mechanisms, including pulsatile release patterns and negative feedback loops.
How Tesamorelin Works
GHRH Receptor Activation
Tesamorelin binds to growth hormone-releasing hormone receptors (GHRH-R) located on somatotroph cells in the anterior pituitary gland. This binding triggers intracellular signaling cascades (primarily through the cAMP/PKA pathway) that stimulate both the synthesis of new growth hormone and the release of stored growth hormone from secretory granules.
Pulsatile GH Release
A critical advantage of tesamorelin over direct HGH injection is its preservation of pulsatile growth hormone secretion. The body normally releases GH in bursts (pulses) throughout the day, with the largest pulse occurring during deep sleep. Tesamorelin amplifies these natural pulses rather than creating a flat, constant elevation of GH. This pulsatile pattern is important because GH receptors can become desensitized to continuous exposure, and the body's negative feedback mechanisms (via somatostatin and IGF-1) remain intact, reducing the risk of supraphysiological GH levels.
IGF-1 Production
The growth hormone stimulated by tesamorelin travels to the liver and other tissues, where it triggers the production of insulin-like growth factor 1 (IGF-1). IGF-1 mediates many of the downstream effects of growth hormone, including its effects on body composition, tissue repair, and metabolism. Clinical trials of tesamorelin have shown increases in IGF-1 levels of approximately 80-100 ng/mL from baseline, generally keeping levels within the normal physiological range.
Visceral Fat Reduction
Tesamorelin's primary clinical effect -- reduction of visceral fat -- occurs through GH-mediated lipolysis. Growth hormone activates hormone-sensitive lipase in adipocytes, promoting the breakdown of stored triglycerides into free fatty acids. Visceral fat cells are particularly responsive to GH-mediated lipolysis because they have a higher density of beta-adrenergic receptors and are more metabolically active than subcutaneous fat cells. This explains why tesamorelin preferentially reduces visceral rather than subcutaneous fat stores.
Benefits of Tesamorelin
Visceral Fat Reduction
The most well-documented benefit of tesamorelin is its ability to reduce visceral adipose tissue. In the pivotal Phase III clinical trials, tesamorelin reduced trunk fat by approximately 15-18% over 26 weeks compared to placebo. This reduction was measured by CT scan, the gold standard for visceral fat quantification. Visceral fat is strongly associated with cardiovascular disease, type 2 diabetes, and metabolic syndrome, making its reduction clinically meaningful beyond cosmetic improvement.
Body Composition
Beyond visceral fat reduction, tesamorelin improves overall body composition. Clinical data showed increases in lean body mass and reductions in waist circumference. In the LIPO-010 trial, patients experienced a mean reduction in waist circumference of approximately 2-3 cm over 26 weeks. Importantly, total body weight may not change substantially, as the loss of fat mass is partially offset by gains in lean tissue.
Cognitive Function
Emerging research has explored tesamorelin's effects on brain health. A study published by Friedman et al. (2013) found that tesamorelin improved cognitive function in older adults with mild cognitive impairment (MCI) or subjective cognitive concerns. Participants who received tesamorelin for 20 weeks showed improvements in executive function and verbal memory. These effects are thought to be mediated by GH and IGF-1, both of which have neurotrophic and neuroprotective properties. A follow-up study confirmed improvements in cognition and favorable changes in cerebrospinal fluid biomarkers of Alzheimer's disease.
Lipid Profile
Tesamorelin has shown beneficial effects on lipid metabolism. Clinical trials demonstrated reductions in triglyceride levels and improvements in the ratio of trunk fat to limb fat. Some data suggest modest improvements in total cholesterol, though results have been mixed across studies. These lipid improvements may contribute to reduced cardiovascular risk in treated patients.
Dosing
FDA-Approved Dosing (Egrifta SV)
- Dose: 1.4mg injected subcutaneously once daily
- Timing: Administered at the same time each day, on an empty stomach or at least 30 minutes before food
- Injection site: Rotate between abdomen (avoiding the navel area), thighs, and upper arms
- Duration: In clinical trials, treatment was continued for 26-52 weeks. FDA labeling does not specify a maximum treatment duration, but efficacy should be reassessed periodically
Common Off-Label Protocols
Off-label use of tesamorelin for body composition and anti-aging purposes typically follows protocols similar to the FDA-approved dosing:
- Standard: 1-2mg subcutaneously once daily, administered before bed or in the morning on an empty stomach
- With ipamorelin: Tesamorelin 1-2mg combined with ipamorelin 100-300mcg, both injected subcutaneously at the same time. This combination leverages two different GH-stimulating pathways for enhanced effect.
- Cycle approach: Some practitioners recommend 5 days on / 2 days off, or 8-12 week cycles with 4-week breaks, to prevent pituitary desensitization. However, the FDA trials used continuous daily dosing for up to 52 weeks without evidence of tachyphylaxis.
- Timing: Best administered on an empty stomach, either first thing in the morning (at least 30 minutes before food) or at bedtime (at least 2-3 hours after the last meal). This timing optimizes GH release, as food (particularly carbohydrates and fats) can blunt the GH response.
Clinical Evidence
Phase III Trials (LIPO-010 and LIPO-011)
The FDA approval of tesamorelin was based on two pivotal Phase III randomized, double-blind, placebo-controlled trials involving over 800 HIV-infected patients with lipodystrophy.
LIPO-010 enrolled 412 patients and demonstrated that 26 weeks of tesamorelin 2mg daily (the original formulation dose) reduced trunk fat by 15.2% from baseline compared to a 5% increase in the placebo group. The difference was statistically significant (p < 0.001). CT-measured visceral adipose tissue decreased by approximately 18% in the treatment group.
LIPO-011 confirmed these findings in 405 patients over a 52-week period. Patients who received tesamorelin for the full 52 weeks maintained their visceral fat reduction, while those switched from tesamorelin to placebo at week 26 saw their visceral fat return to baseline levels. This demonstrated that the benefits require ongoing treatment.
Cognitive Studies
Friedman et al. (2013) conducted a randomized, double-blind, placebo-controlled trial in 152 older adults (ages 55-87) examining tesamorelin's effects on cognition. The treatment group showed significant improvements in executive function and verbal memory compared to placebo over 20 weeks, with particularly strong effects in participants with MCI.
Timeline of Effects
- Weeks 1-4: GH and IGF-1 levels begin to rise. Improved sleep quality and recovery are commonly the first subjective effects noticed. Some users report improved energy.
- Weeks 4-8: Body composition changes begin to become noticeable. Reduced waist circumference, improved skin quality, and enhanced recovery from exercise.
- Weeks 8-16: Significant visceral fat reduction becomes measurable. Improvements in lean body mass. Lipid profile changes may appear on bloodwork.
- Weeks 16-26: Full clinical effects as demonstrated in trials. Maximum visceral fat reduction is typically achieved by week 26, with continued maintenance thereafter.
- Beyond 26 weeks: Benefits are maintained with continued use. Discontinuation leads to gradual return of visceral fat over subsequent months.
Side Effects
Clinical trials have documented the following side effects:
Common (>5% of patients): - Injection site reactions (redness, swelling, itching, pain) -- the most frequently reported side effect - Arthralgia (joint pain) - Peripheral edema (fluid retention, particularly in hands and feet) - Myalgia (muscle pain)
Less Common (1-5% of patients): - Paresthesia (numbness or tingling) - Carpal tunnel syndrome or carpal tunnel-like symptoms - Increased blood glucose levels - Nausea - Pruritus (itching)
Important Considerations: - Tesamorelin is contraindicated in patients with active malignancy, as GH can promote tumor growth - Patients with a history of pituitary surgery, irradiation, or other conditions affecting the pituitary may have reduced or absent response - Blood glucose should be monitored, particularly in patients with diabetes or prediabetes - IGF-1 levels should be checked periodically to ensure they remain within the normal range
Frequently Asked Questions
What is tesamorelin? Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog. It is FDA-approved under the brand name Egrifta for reducing excess abdominal fat in HIV patients with lipodystrophy. It stimulates the pituitary gland to produce growth hormone naturally.
How is tesamorelin different from HGH? Tesamorelin stimulates your body to produce its own growth hormone through the natural pulsatile release pattern, rather than injecting exogenous growth hormone directly. This maintains the body's feedback loops and has a better safety profile than HGH.
Does tesamorelin reduce belly fat? Yes. Clinical trials demonstrated that tesamorelin reduced visceral adipose tissue (VAT) by approximately 15-18% over 26 weeks. It specifically targets visceral (deep abdominal) fat rather than subcutaneous fat.
What are the side effects of tesamorelin? Common side effects include injection site reactions, joint pain, and peripheral edema (fluid retention). Less common effects include increased blood glucose and carpal tunnel-like symptoms. These are typically mild and dose-dependent.
Can you combine tesamorelin with ipamorelin? Yes, tesamorelin and ipamorelin are commonly combined. Tesamorelin (GHRH analog) stimulates GH release while ipamorelin (ghrelin mimetic) amplifies the signal through a different pathway, resulting in enhanced GH output.
Does tesamorelin work without exercise? Yes. The clinical trials did not require participants to exercise, and significant visceral fat reduction was still observed. However, combining tesamorelin with regular exercise and a healthy diet will amplify the results, as exercise independently stimulates GH release and fat oxidation.
Will the fat come back if I stop tesamorelin? Clinical trial data from the LIPO-011 study showed that visceral fat returned to baseline levels within 6-12 months after discontinuing tesamorelin. This suggests that ongoing treatment is needed to maintain the fat reduction benefits.
Sources
-
Falutz, J., Allas, S., Blot, K., et al. (2007). "Metabolic effects of a growth hormone-releasing factor in patients with HIV." New England Journal of Medicine, 357(23), 2359-2370. doi:10.1056/NEJMoa072375
-
Falutz, J., Potvin, D., Mamputu, J.C., et al. (2010). "Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data." Journal of Clinical Endocrinology & Metabolism, 95(9), 4291-4304. doi:10.1210/jc.2010-0490
-
Stanley, T.L., Feldpausch, M.N., Oh, J., et al. (2014). "Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial." JAMA, 312(4), 380-389. doi:10.1001/jama.2014.8334
-
Friedman, S.D., Baker, L.D., Borber, S., et al. (2013). "Growth hormone-releasing hormone effects on brain gamma-aminobutyric acid levels in mild cognitive impairment and healthy aging." JAMA Neurology, 70(7), 883-890. doi:10.1001/jamaneurol.2013.1425
-
Makimura, H., Feldpausch, M.N., Stanley, T.L., et al. (2012). "Reduced growth hormone secretion in obesity is associated with smaller LDL and HDL particle size." Clinical Endocrinology, 76(2), 220-227. doi:10.1111/j.1365-2265.2011.04195.x
-
Theratechnologies Inc. (2019). "Egrifta SV (tesamorelin for injection) Prescribing Information." U.S. Food and Drug Administration.